The ribosomal targets of MeCP2 in the human brain are an emerging subject of research in the context of Rett Syndrome as mutations in the MECP2 gene lead to various molecular and cellular alterations, including disruptions in ribosomal RNA (rRNA) transcription and maturation, which are mainly controlled by signaling by nucleolin and the pathways of mechanistic target of rapamycin (mTOR)–P70S6K (Olson et al., 2018). This evidence concerns the gene MTOR and Rett syndrome.